Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
39.09B
Market cap39.09B
Price-Earnings ratio
67.98
Price-Earnings ratio67.98
Dividend yield
Dividend yield
Average volume
992.67K
Average volume992.67K
High today
$302.50
High today$302.50
Low today
$283.10
Low today$283.10
Open price
$284.84
Open price$284.84
Volume
988.48K
Volume988.48K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$283.10
52 Week low$283.10

Stock Snapshot

With a market cap of 39.09B, Alnylam Pharmaceuticals(ALNY) trades at $302.50. The stock has a price-to-earnings ratio of 67.98.

As of 2026-06-04, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $283.10 and $302.50. The current price stands at $302.50, placing the stock +6.9% above today's low and 0.0% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 988.48K, compared to an average daily volume of 992.67K.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $283.10 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $283.10 at its lowest and $495.55 at its peak.

ALNY News

Investing.com 4h
Alnylam, Inceptive form AI drug discovery collaboration - Investing.com

...

Alnylam, Inceptive form AI drug discovery collaboration - Investing.com
TipRanks 7h
Alnylam, Inceptive form strategic AI collaboration

The company states: “Alnylam (ALNY) Pharmaceuticals and Inceptive Nucleics, Inc. announced a strategic collaboration agreement to increase the pace of therapeut...

Nasdaq 4d
Are Options Traders Betting on a Big Move in Alnylam Stock?

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market lately. That is because the July 1...

Are Options Traders Betting on a Big Move in Alnylam Stock?

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
29%
Sell
0%

More ALNY News

Simply Wall St 6d
How Investors May Respond To Alnylam Pharmaceuticals Adding Scientific Depth Amid RNAi Pipeline Scrutiny

Alnylam Pharmaceuticals recently expanded its Board of Directors from ten to eleven members and appointed Benjamin F. Cravatt, Ph.D., as a Class III director th...

How Investors May Respond To Alnylam Pharmaceuticals Adding Scientific Depth Amid RNAi Pipeline Scrutiny

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.